EXELIXIS, INC. (EXEL) Form 8-K — Oct 29, 2026
Exelixis reported Q3 2026 total revenues of $658.7 million, up from $597.8 million a year ago, with GAAP diluted EPS of $0.85 versus $0.69, driven by U.S. cabozantinib franchise net product revenues of $604.9 million and a 3.0% price increase effective January 2026. The company maintained FY2026 total revenue guidance of $2.500-$2.550 billion while lowering its effective tax rate guidance to 16%-18%, and has repurchased $402.1 million under its $750 million May 2026 buyback program.
Key figures
- Eps
- 0.85
- Revenue
- 658700000
- Guidance
- FY2026 total revenues $2.500-$2.550 billion; net product revenues $2.300-$2.350 billion; R&D $825M-$875M; SG&A $575M-$625M; effective tax rate lowered to 16%-18% from 21%-23%
- Net Income
- 218100000
- Revenue Yoy
- 10.2%
- Royalty revenues
- $51.8 million
- Non gaap diluted eps
- 0.94
- May 2026 srp repurchased
- $402.1 million at avg $54.03/share
- Cumulative buybacks since 2023
- $3.2 billion, 97.8 million shares at avg $32.25/share
- Cabozantinib us net product revenues
- $604.9 million
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.